Epilepsy, Seizures
Conditions
Keywords
EEG Monitoring
Brief summary
The goal of this clinical trial is to test Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days) in patients presenting with questionable seizure characterization. The main questions it aims to answer are: • Can more seizure events be recorded in fourteen (14) days than can be recorded in three (3) days? • Do treating clinicians find clinical value in extended fourteen (14) - twenty-eight (28) days of EEG? Participants will wear a portable EEG device (REMI) for fourteen (14) to twenty-eight (28) days in their home/community setting.
Detailed description
This is a prospective study to quantify Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days). Patients presenting with questionable seizure characterization that are scheduling a conventional at home ambulatory EEG (Amb EEG) and who meet the study inclusion and exclusion criteria will be prescribed a REMI system. The purpose of this study is to demonstrate that the REMI system is able to record EEG data that clinicians can use to identify ictal events over extended periods, and that extended clinical EEG data is valuable in the diagnosis and treatment of seizure related symptoms.
Interventions
DEVICEEpitel's™ Remote EEG Monitoring System's (REMI™)
Ambulatory electroencephalography (EEG) monitoring
Sponsors
Epitel, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Prospective Cohort
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients have a reported history of seizures (epileptic, non-epileptic, or unknown), * Have a minimum reported seizure rate of one every two weeks, * Are prescribed an ambulatory EEG study as part of routine care, * Is Male or Female between the ages of 18 and 70, * Can understand and sign written informed consent, or have a legal guardian provide consent, * The Patient (or Primary Caregiver) must be competent to follow all study procedures, * The Patient must be willing to use the System for a prolonged period (up to 30 days), for a minimum of 20 hours/day.
Exclusion criteria
* Is sensitive or allergic to medical acrylics, silicones, or hydrogels, * Is enrolled in another investigational drug or device trial, * Is homeless or in a home without a power supply, or * Cannot read, speak, or understand English (and does not have a translator).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ictal Events Identified in fourteen (14) days. | Fourteen (14) days | Epileptiform seizure activity as identified by three independent board-certified epileptologists assessing data collected by REMI. The number of seizures identified in the first three days will be compared to the number of seizures identified during days one (1) to fourteen (14). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Extended Use | Twenty-eight (28) days | Epileptiform seizure activity as identified by three independent board-certified epileptologists assessing data collected by REMI. The number of seizures identified in the first fourteen (14) days will be compared to the number of seizures identified during all twenty-eight (28) days. |
Countries
United States
Outcome results
None listed